Evaluation of the SSTR2-targeted Radiopharmaceutical 177Lu-DOTATATE and SSTR2-specific 68Ga-DOTATATE PET as Imaging Biomarker in Patients with Intracranial Meningioma
Sylvia C. Kurz(Center for Neuro-Oncology), Erik P. Sulman(NYU Langone Health), Elçin Zan(Cornell University), Marissa Barbaro(NYU Langone Health), David Zagzag(NYU Langone Health), Douglas Kondziolka(Neurological Surgery), John G. Golfinos(NYU Langone Health), Matija Snuderl, Andrew Chi(Therapeutics Clinical Research), Christine Cordova(Cleveland Clinic), Joshua S. Silverman(NYU Langone Health), Andrea B. Troxel(Andover Eye Associates)
Cited by 55
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19
|New England Journal of Medicine|2020|1.1k